X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the license agreement, Otsuka holds exclusive rights to develop, manufacture, and commercialize SEP-363856 (ulotaront), TAAR1 agonist. It is being evaluated with the patient for the treatment of Schizophrenia.
Lead Product(s): Ulotaront
Therapeutic Area: Psychiatry/Psychology Product Name: SEP-363856
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 15, 2024
Details:
Orgovyx (relugolix) is a nonpeptide GnRH receptor antagonist that competitively binds to pituitary GnRH receptors. It is launched in Canada for testosterone suppression in patients with advanced prostate cancer.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Product Name: Orgovyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
ORGOVYX (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Product Name: Orgovyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2023
Details:
Orogvyx (relugolix), is the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist, for the treatment of men with advanced prostate cancer.
Lead Product(s): Relugolix
Therapeutic Area: Oncology Product Name: Orgovyx
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
Under the agreement, Veneno will conduct a program to obtain functional peptides (DRPs) for ion channels targeted by Sumitomo Pharma using Veneno Technologies' next-generation peptide discovery technology, the PERISS™ method (intra-periplasm secretion and selection).
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Recipient: Veneno Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 18, 2023
Details:
The agreement includes the marketing alliance for JR-051 (agalsidase beta BS), a biosimilar of Fabrazyme, a therapeutic enzyme, being sold by JCR for the treatment of Fabry disease.
Lead Product(s): Agalsidase Beta
Therapeutic Area: Genetic Disease Product Name: JR-051
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: JCR Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 01, 2022
Details:
It appears from nonclinical data that KSP-1007 broadly and strongly inhibits β-lactamases, which are enzymes that are produced by bacteria that can degrade carbapenem antibiotics. Sumitovant is leading the program of the compound in the U.S.
Lead Product(s): KSP-1007,Meropenem
Therapeutic Area: Infections and Infectious Diseases Product Name: KSP-1007
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Sumitovant Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 10, 2022
Details:
This study evaluated the safety and efficacy of DSP-7888, an investigational WT1 immunotherapeutic cancer vaccine, in combination with bevacizumab versus bevacizumab alone in patients with recurrent or progressive GBM following initial therapy.
Lead Product(s): Ombipepimut,Bevacizumab
Therapeutic Area: Oncology Product Name: DSP-7888
Highest Development Status: Phase IIIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
The companies entered into a strategic partnership for the development and commercialization of Twymeeg (imeglimin hydrochloride) in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.
Lead Product(s): Imeglimin Hydrochloride
Therapeutic Area: Endocrinology Product Name: Twymeeg
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Poxel
Deal Size: $299.0 million Upfront Cash: $42.0 million
Deal Type: Partnership June 23, 2021
Details:
Clinical study of DSP-0038, a dual targeted 5-HT1A agonist and 5-HT2A antagonist to be assessed for treatment of Alzheimer’s disease psychosis.
Lead Product(s): DSP-0038
Therapeutic Area: Neurology Product Name: DSP-0038
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Exscientia
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
